Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Plasma Medicine
SJR: 0.278 SNIP: 0.183 CiteScore™: 0.57

ISSN Imprimer: 1947-5764
ISSN En ligne: 1947-5772

Plasma Medicine

DOI: 10.1615/PlasmaMed.2019030124
pages 89-99

Optimum Power of Low-Temperature Plasma Selectivity for Human Melanoma Cell Treatment

Sarut Chaisrisawadisuk
Division of Plastic Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Dheerawan Boonyawan
Department of Physics and Materials Science, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand
Apirag Chuangsuwanit
Division of Plastic Surgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand


The number of new cases of melanoma is increasing every year. Due to its specificity of treatment, plasma medicine has been claimed to be a novel adjunctive procedure. We evaluated the effects of a direct low-temperature plasma (LTP) device for selective tumor eradication, comparing between melanoma and normal keratinocyte cell lines. Human melanoma (G-361) and normal keratinocyte (HaCaT) cell lines were subjected to LTP treatment. Different power levels and exposure durations of LTP were compared in both groups. After the treatment, a MTT assay was used to determine cell viability. The physical plasma characteristics of the three powers were also evaluated. It was found that low power (intensity 1 with frequency 10 Hz) was 0.25 watts, while medium power (intensity 5 with frequency 50 Hz) and high power (intensity 10, with frequency 100 Hz) were 0.94 and 3.0 watts, respectively. Higher powers and longer durations of LTP treatment increased the incidence of cell death in both the HaCaT and G-361 cell lines. LTP eliminated slightly more G-361 than HaCaT cells at 10 and 30 seconds of exposure. At 60 seconds or more, LTP showed a decrease of more than 50% in both the HaCaT and G-361 survival. Medium LTP power with 10-second exposure demonstrated a statistically significant difference between HaCaT and G-361 viabilities (77.1% and 66.3%, respectively; P = 0.01). LTP treatment at medium power (intensity 5 with frequency 50 Hz, equal to 0.94 watts) at 10-second duration showed a specificity for cancer eradication.


  1. Fridman G, Friedman G, Gutsol A, Shekhter AB, Vasilets VN, Fridman A. Applied plasma medicine. Plasma Process Polym. 2008;5(6):503-33.

  2. Volotskova O, Hawley TS, Stepp MA, Keidar M. Targeting the cancer cell cycle by cold atmospheric plasma. Sci Rep. 2012;2:636.

  3. Schlegel J, Koritzer J, Boxhammer V Plasma in cancer treatment. Clin Plasma Med. 2013;1(2):2-7.

  4. Keidar M. Plasma for cancer treatment. Plasma Sources Sci Technol. 2015;24(3):033001.

  5. Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R, Guerrero-Preston R, Trink B. Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. Br J Cancer. 2011;105(9):1295-301.

  6. Guerrero-Preston R, Ogawa T, Uemura M, Shumulinsky G, Valle BL, Pirini F, Ravi R, Sidransky D, Keidar M, Trink B. Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. Int J Mol Med. 2014;34(4):941-6.

  7. Zucker SN, Zirnheld J, Bagati A, DiSanto TM, Des Soye B, Wawrzyniak JA, Etemadi K, Nikiforov M, Berezney R. Preferential induction of apoptotic cell death in melanoma cells as compared with normal keratinocytes using a non-thermal plasma torch. Cancer Biol Ther. 2014;13(13):1299-306.

  8. Kong MG, Kroesen G, Morfill G, Nosenko T, Shimizu T, van Dijk J, Zimmermann JL. Plasma medicine: an introductory review. New J Phys. 2009;11(11):115012.

  9. Vandamme M, Robert E, Lerondel S, Sarron V, Ries D, Dozias S, Sobilo J, Gosset D, Kieda C, Legrain B, Pouvesle JM, Pape AL. ROS implication in a new antitumor strategy based on nonthermal plasma. Int J Cancer. 2012;130(9):2185-94.

  10. Sensenig R, Kalghatgi S, Cerchar E, Fridman G, Shereshevsky A, Torabi B, Arjunan KP, Podolsky E, Fridman A, Friedman G, Azizkhan-Clifford J, Brooks AD. Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species. Ann Biomed Eng. 2011;39(2):674-87.

  11. Howlader N, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ. SEER cancer statistics review, 1975-2013 Bethesda, MD.: National Cancer Institute; 2016. Available from: http://seer.cancer.gov/csr/1975_2013/.

  12. Daeschlein G, Scholz S, Lutze S, Arnold A, von Podewils S, Kiefer T, Tueting T, Hardt O, Haase H, Grisk O, Langner S, Ritter C, von Woedtke T, Junger M. Comparison between cold plasma, electrochemotherapy and combined therapy in a melanoma mouse model. Exp Dermatol. 2013;22(9):582-6.